What we’re reading, January 5, 2017: Vice President Joe Biden will create a nonprofit organization to focus on cancer research and drug prices; school telemedicine could help kids stay in the classroom and out of the doctor’s office; bundled payments for joint replacements saved $5577 in spending per episode.
After 2 terms as vice president and endeavors like the Cancer Moonshot Initiative and the 21st Century Cures Act, Joe Biden does not plan to rest when he leaves office this month. In an interview with The Washington Post, Biden announced he would create a new nonprofit, tentatively called the Biden Cancer Initiative, to encourage oncology research. He also said that another major focus would be lowering the price of cancer drugs, especially for underserved populations.
According to a Pew report, telemedicine in schools could be a “game changer” for children’s health, allowing them to stay in the classroom longer by reducing unnecessary trips to a physician’s office or even the emergency room. Advocates predict that more school districts will use virtual medicine for managing chronic conditions or providing mental health counseling, not just addressing acute health complaints. However, a major barrier to implementation is the lack of coverage; just 18 states authorize Medicaid reimbursement for school telemedicine.
A JAMA investigation found a cost savings of $5577 per joint replacement episode when using the Medicare bundled payment model. The major drivers of the savings were reductions in implant costs and lower post-acute spending, including inpatient rehabilitation and skilled nursing facility costs. Readmissions and emergency department visits declined slightly, and episodes with a prolonged length of stay decreased 67%.
Exploring Racial, Ethnic Disparities in Cancer Care Prior Authorization Decisions
October 24th 2024On this episode of Managed Care Cast, we're talking with the author of a study published in the October 2024 issue of The American Journal of Managed Care® that explored prior authorization decisions in cancer care by race and ethnicity for commercially insured patients.
Listen
Obesity at Cancer Diagnosis Linked to Worse Survival Outcomes in Pediatric Patients
January 13th 2025Pediatric patients considered obese at cancer diagnosis are linked to significantly worse survival outcomes, especially those with acute lymphoblastic leukemia and central nervous system tumors.
Read More
Examining Low-Value Cancer Care Trends Amidst the COVID-19 Pandemic
April 25th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the April 2024 issue of The American Journal of Managed Care® about their findings on the rates of low-value cancer care services throughout the COVID-19 pandemic.
Listen
FDA Approves Tislelizumab-jsgr as First-Line Therapy for HER2– Gastric Cancers
January 2nd 2025Tislelizumab-jsgr (Tevimbra) was approved in combination with chemotherapy for the treatment of unresectable or metastatic HER2-negative (HER–) gastric or gastroesophageal junction adenocarcinoma (G/GEJ) in adults whose tumors express PD-L1.
Read More